Back to top
Clinical stage:
In vitro

Currently undergoing in-vitro reformulation and is N4 Pharma's most advanced opportunity

N4 Pharma is seeking to improve the speed at which Sildenafil (commonly known as Viagra) takes effect whilst also extending its duration of action.

The erectile dysfunction market had global annual sales of approximately $4.6 billion* in 2016 and is expected to drop to $3.2 billion by 2022 due to the expected patent expiry of Viagra and Cialis.

*Source: Evaluate Pharma